Skip to content
Screener

MBX Biosciences, Inc. MBX Q3 2025 earnings

Reported November 6, 2025 · Before market open

EPS-$0.63Beat by $0.10
EPS estimate-$0.73

Next report

Nov 5, 2026 (in 3 months)
EPS estimate-$0.74

Financials

Q3 2025

Income statement

See full
Operating income-$23.9M-22.0%
Net income-$21.6M-19.2%
EPS (diluted)-$0.63+77.3%

Balance sheet

See full
Cash & equivalents$223.1M+67.9%
Total debt$623.0K+197%
Total equity$387.5M+42.8%
Total assets$400.1M+41.7%

Cash flow

See full
Operating cash flow-$21.5M-46.9%
CapEx$399.0K+600%
Free cash flow-$21.9M-49.0%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$782.52M—
Enterprise value$560.02M—

Returns & leverage

See full
Return on equity-24.4%—
Debt / equity0×0.0×
Current ratio33×+7.2×

FAQ

When did MBX Biosciences, Inc. report Q3 2025 earnings?
MBX Biosciences, Inc. (MBX) reported Q3 2025 earnings on November 6, 2025 before market open.
What were MBX Biosciences, Inc.'s Q3 2025 revenue and EPS?
MBX Biosciences, Inc. reported eps of $-0.63 for Q3 2025.
Did MBX Biosciences, Inc. beat estimates in Q3 2025?
EPS beat the consensus estimate of $-0.73 by $0.10.
How did MBX Biosciences, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 77.3% from $-2.78.
Where can I find MBX Biosciences, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001193125-25-268146) and the 10-Q periodic report (0001193125-25-268148) directly on SEC EDGAR. The filing index links above go to sec.gov.